| Value | ₹0.30 Cr |
|---|---|
| Execution period | Vesting period is one year; exercise period is two years from vesting. |
BSE filing, NSE: MARKSANS. Summary written from the filing by ALFA Finder's alert engine.
Marksans Pharma Ltd: key numbers
- Share price
- ₹301.00
- Market cap
- ₹13,640 Cr
- Revenue (annual)
- ₹2,951 Cr
- Net profit (annual)
- ₹417.9 Cr
- P/E (TTM)
- 24.4×Sector 41.3×
- Promoter holding
- 43.87%+0.00% QoQ
- FII holding
- 19.06%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Marksans Pharma Ltd
All →Marksans Pharma Employee Stock Options
Marksans Pharma allotted 56,250 equity shares to employee stock option grantees under its 2024 scheme. Shares were issued on exercise of vested options.
Marksans Pharma Results Update
Marksans Pharma reported Q2FY27 revenue of ₹940 crore and H1FY27 PAT of ₹303 crore. EBITDA grew 48% to a record ₹214 crore in the quarter.
Marksans Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue ₹940cr (+30.5% YoY), EBITDA ₹214cr at 22.8% margin (+274bps), PAT ₹143.5cr (+44.8%). H1 PAT ₹303cr; net cash ₹1,095cr; Europe front-end being built.
Marksans Pharma Q2 FY27 Results: Net Profit ₹143.5 Cr, Up 44.8% YoY
Marksans Pharma Ltd reported revenue from operations of ₹940.2 Cr (+30.5% YoY) and net profit of ₹143.5 Cr (+44.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹143.5 Cr · +44.8% YoY
Marksans Pharma Board Meeting Date
Marksans Pharma scheduled its Board meeting for November 4, 2026, to approve Q1/H1 unaudited results. No material decision has been taken yet.
Marksans Pharma Other Announcement
Periodic quarterly shareholding pattern filing for Marksans Pharma Ltd. This document provides the latest breakdown of shareholder categories as mandated by SEBI.
Other employee stock options announcements
All →ICICI Life Insurance Employee Stock Options
ICICI Life allotted 2,520 equity shares under its Employees Stock Unit Scheme (2023) on November 4, 2026. The shares rank pari passu with existing equity.
Share India Securities Employee Stock Options
Share India Securities granted 3,80,500 employee stock options under its ESOS-II scheme. Each option converts to one equity share at a Rs.2 exercise price.
- Execution
- Exercisable from vesting, expiring not later than 1 year after the last vesting date
Bluspring Enterprises Employee Stock Options
Bluspring Enterprises allotted 38,711 equity shares under its Special Purpose SOP 2025 on November 4, 2026. Paid-up capital rose to Rs.149.54 Crore after the allotment.
Vedanta Oil and Gas Employee Stock Options
Vedanta Oil and Gas's performance-based ESOS 2016 grants vested for 55,16,340 options, priced at par. Exercise is open for 8 months, with exercise money not yet determined.
- Execution
- 8 months from vesting date (November 04, 2026), or such other period as approved by the NRC
Aditya Birla Capital Employee Stock Options
Aditya Birla Capital allotted 148,098 equity shares on November 4, 2026, under its ESOP and RSU/PSU schemes. Paid-up capital rises to ₹27,38,15,47,350 after the allotment.
Wipro Employee Stock Options
Wipro allotted 95,503 equity shares under employee RSU and ESOP schemes. The allotment reflects routine employee share issuance with no stated consideration.